Thus, it is of importance to analyze patient-reported outcomes not only in clinical studies but also in less-selected NASH populations, to generate evidence of the patient’s quality of life and identify variables that may impair the use of FXR agonists outside of clinical trials. Here, NR1H4 is linked to metabolic dysfunction-associated steatohepatitis.